Market Cap | 113.44M | P/E | - | EPS this Y | -3,000.00% | Ern Qtrly Grth | - |
Income | 11.09M | Forward P/E | -1.86 | EPS next Y | -96.80% | 50D Avg Chg | - |
Sales | 119.57M | PEG | 4.30 | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | -0.90% | 52W High Chg | -43.00% |
Recommedations | 2.10 | Quick Ratio | 0.98 | Shares Outstanding | 78.12M | 52W Low Chg | 46.00% |
Insider Own | 1.00% | ROA | 1.94% | Shares Float | 66.34M | Beta | 1.04 |
Inst Own | 72.26% | ROE | - | Shares Shorted/Prior | 6.98M/7.87M | Price | 1.71 |
Gross Margin | 100.00% | Profit Margin | 9.27% | Avg. Volume | 379,900 | Target Price | 5.31 |
Oper. Margin | -33.65% | Earnings Date | Nov 5 | Volume | 196,695 | Change | 1.18% |
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
HC Wainwright & Co. | Neutral | Sep 13, 24 |
HC Wainwright & Co. | Neutral | Aug 22, 24 |
HC Wainwright & Co. | Neutral | Jun 27, 24 |
Piper Sandler | Overweight | May 28, 24 |
BMO Capital | Market Perform | May 9, 24 |
HC Wainwright & Co. | Neutral | May 9, 24 |
Wedbush | Outperform | May 9, 24 |
Jefferies | Buy | May 6, 24 |
BMO Capital | Market Perform | May 1, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BELVIN MARCIA | SVP, Chief Scientifi.. SVP, Chief Scientific Officer | Sep 20 | Sell | 1.3 | 4,119 | 5,355 | 147,951 | 09/22/23 |
Landau Jeffrey B | Chief Business Offic.. Chief Business Officer | Sep 20 | Sell | 1.3 | 4,119 | 5,355 | 76,379 | 09/22/23 |
McCarthy Sean A. | CEO CEO | Sep 20 | Sell | 1.3 | 14,601 | 18,981 | 430,755 | 09/22/23 |
ROWLAND LLOYD A | General Counsel General Counsel | Sep 20 | Sell | 1.3 | 5,486 | 7,132 | 80,609 | 09/22/23 |
McCarthy Sean A. | CEO CEO | May 19 | Option | 1.5749 | 16,535 | 26,041 | 405,356 | 05/23/23 |
Jones Elaine V | Director Director | Mar 29 | Buy | 1.55 | 5,000 | 7,750 | 5,142 | 03/31/23 |
Ogden Christopher | SVP, Finance and Acc.. SVP, Finance and Accounting | Mar 16 | Sell | 1.9793 | 516 | 1,021 | 37,772 | 03/20/23 |
Campoy Carlos | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Sell | 1.9791 | 1,748 | 3,459 | 38,224 | 03/20/23 |
McCarthy Sean A. | CEO CEO | Mar 16 | Sell | 1.8805 | 7,121 | 13,391 | 388,821 | 03/20/23 |
ROWLAND LLOYD A | General Counsel General Counsel | Mar 16 | Sell | 1.979 | 2,037 | 4,031 | 71,095 | 03/20/23 |
Landau Jeffrey B | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Sell | 1.9792 | 1,477 | 2,923 | 69,248 | 03/20/23 |
Peterson Amy C. | EVP, Chief Developme.. EVP, Chief Development Officer | Mar 16 | Sell | 1.979 | 4,257 | 8,425 | 58,433 | 03/20/23 |
McCarthy Sean A. | President and CEO President and CEO | May 09 | Option | 0.95 | 90,931 | 86,384 | 265,853 | 05/11/22 |
McCarthy Sean A. | President and CEO President and CEO | Jun 16 | Option | 1.04 | 40 | 42 | 7,849 | 06/16/21 |
McCarthy Sean A. | President and CEO President and CEO | Apr 02 | Option | 1.13 | 100,000 | 113,000 | 306,894 | 04/02/21 |